Best Exosome / Extracellular Vesicle CDMOs in Switzerland
0
CDMOs tracked
0
Fully scored
Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|
What to evaluate in a Exosome / Extracellular Vesicle CDMO
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Why are Swiss CDMOs positioned as premium-tier for biopharma manufacturing?
The Swiss CDMO cluster (Basel, Visp, Bern) hosts three attributes that reinforce a premium tier positioning: (1) regulatory alignment — Switzerland's Swissmedic runs a mutual-recognition GMP framework with the EU, so a Swiss facility supplying the EU doesn't need parallel EMA certification for the same activities; (2) technical depth — Swiss CDMOs have historically led on complex chemistry (Lonza on biologics + peptides, Bachem on peptides, CordenPharma on APIs) and on early-adopter viral vector manufacturing; (3) capital access — Swiss operations are able to make sustained capex investments in single-site scale-ups that lower-cost jurisdictions cannot match. That said, Swiss CDMOs also carry higher per-batch costs than Asian or Eastern European alternatives — the trade-off is process depth and regulatory posture, not price.
How does Switzerland's non-EU status affect drug supply to EU markets?
Switzerland is not an EU member state but maintains a bilateral Mutual Recognition Agreement (MRA) with the EU covering GMP inspections. Practically: a Swissmedic GMP inspection is recognized by EMA as equivalent to an EMA GMP inspection for the covered activity. Swiss-manufactured product does still require an EU-based Qualified Person for batch release into the EU market, but the facility itself does not need parallel EMA certification. This makes Swiss CDMOs operationally cleaner for pan-European supply than most non-EU alternatives. For UK supply, post-Brexit MHRA has continued to recognize the Swissmedic MRA under transitional arrangements — sponsors supplying both EU and UK should confirm current MHRA policy at RFP stage.
Which Swiss CDMOs are also present in the US and Asia?
The largest Swiss CDMOs — Lonza, CordenPharma, Bachem — operate global site networks spanning Switzerland, US, and (in Lonza's case) multiple Asian geographies. This multi-region posture materially reduces regulatory tech-transfer risk for programs supplying multiple markets from a single CDMO relationship. Cross-check with the US region ranking and Asia region ranking to identify Swiss-headquartered CDMOs with cross-jurisdictional footprint. Individual profile pages surface the specific site network.
Exosome / Extracellular Vesicle CDMOs — Frequently Asked Questions
What should I look for in an exosome CDMO?
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.
Related modalities